While synuclein proteins are common targets of clinical trials for PD, Lewy Body Dementia and Multiple System Atrophy, few trials are currently targeting synuclein proteins to screen patients or to improve outcomes in AD (https://clinicaltrials.gov/). This evidence concerns the gene SNCA and Parkinson disease.